血管疾病中的谷氨酸酶1:将代谢重编程与动脉样硬化进展和稳定性联系起来
Xi-Long Zheng1, Hao Yin2, Zhihan Tang3
1Departments of Biochemistry & Molecular Biology and Physiology & Pharmacology, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. xlzheng@ucalgary.ca.
Journal of cardiovascular translational research
|March 11, 2026
概括
谷氨酸酶-1 (GLS1) 是动脉样硬化的关键代谢酶. 它精确的,时间有限的调制显示了通过向特定的细胞状态和疾病阶段来治疗心血管疾病的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 谷氨酸酶-1 (GLS1) 催化谷氨酸到谷氨酸,支持细胞新陈代谢.
- 在复杂的心血管疾病 - - 动脉样硬化中GLS1的作用需要在不同疾病阶段和细胞类型中进行详细的研究.
研究的目的:
- 在动脉样硬化中定义GLS1的细胞和阶段特异性功能.
- 探索GLS1调制在心血管疾病治疗中的转化机会.
主要方法:
- 综合来自动物,细胞和人类 (批量和单细胞) 研究的数据.
- 分析GLS1对血管光滑肌细胞 (VSMC),内皮细胞和巨细胞的影响.
- 探索GLS1与血管衰老和铁亡的联系.
主要成果:
- 在早期的动脉样硬化中,GLS1促进血管光滑肌的增殖,内皮发芽和炎症性巨细胞激活.
- 在先进的斑块中,GLS1支持纤维状盖VSMC的存活,内皮屏障功能和细胞,可能会限制缩.
- 过量的谷氨酸可能会导致化;GLS1与血管衰老和铁亡有关.
结论:
- GLS1作为动脉样硬化中的可调节的代谢检查点,具有取决于背景的效果.
- 精确,时间有限的GLS1调制 (例如,telaglenastat) 可能提供治疗效益,可能补充现有的心血管疗法.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Proteoglycans
5.1K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
5.1K
